Essential hypertension: psychiatric aspects and use of psychotropics.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000700:Analgesics / Q000494:pharmacology; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D000928:Antidepressive Agents / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003866:Depressive Disorder / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000523:psychology*; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D008094:Lithium / Q000494:pharmacology; D016651:Lithium Carbonate; D011619:Psychotropic Drugs / Q000494:pharmacology* / Q000627:therapeutic use; D012110:Reserpine / Q000009:adverse effects; D014665:Vasodilator Agents / Q000009:adverse effects
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D000959:Antihypertensive Agents; D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives; D011619:Psychotropic Drugs; D014665:Vasodilator Agents; D016651:Lithium Carbonate; D012110:Reserpine; D008094:Lithium